The Food and Drug Administration, the National Institute of Allergy and Infectious Diseases (NIAID) and the Infectious Diseases Society of America (IDSA) will host a two-day workshop to bring together experts to discuss the scientific data addressing key issues in the science and mechanisms of bacterial resistance as well as the science of antibacterial drug development.
The Food and Drug Administration, the National Institute of Allergy and Infectious Diseases (NIAID) and the Infectious Diseases Society of America (IDSA) will host a two-day workshop to bring together experts to discuss the scientific data addressing key issues in the following areas:
-- Scale of the current bacterial resistance problem including extent, trajectory, and cost
-- Science and mechanisms of bacterial resistance
-- Science of development of rapid diagnostic devices
-- Science of antibacterial drug development
The event will be held July 26-27 at the Crowne Plaza Hotel in Silver Spring, Md. Registration is free for the public workshop. Interested parties are encouraged to register early because space is limited. Seating will be available on a first-come, first-served basis. To register electronically, email registration information (including name, title, firm name, address, telephone, and fax number) to arworkshop@fda.hhs.gov.
The workshop will be simultaneously web-cast. The public may view the live webcast free by pre-registering below until 24 hours prior to the workshop. IDSA will do its best to accommodate members of the public who register after this time.
For more details and to register, CLICK HERE.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.
Robust infectious disease surveillance, including rapid subtyping of influenza A, is essential for early detection, containment, and public health reporting of novel viral threats.